How will the nurse minimize the risk for infection when changing a patients IV catheter site dressing?

1. Mermel LA. Prevention of intravascular catheter-related infections. (Erratum: Ann Intern Med 133:395, 2000). Ann Intern Med. 2000;132:391–402. [PubMed] [Google Scholar]

Inhaltsverzeichnis Show

What technique should be used to change an IV site dressing?
Why is it important to label the gauze dressing covering the site of an intravenous access device with the date time and nurses initials?
When should an IV dressing be changed?
How do you protect an IV site?

2. Dimick JB, Pelz RK, Consunji R, Swoboda SM, Hendrix CW, Lipsett PA. Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. Arch Surg. 2001;136:229–34. [PubMed] [Google Scholar]

3. Warren DK, Quadir WW, Hollenbeak CS, Elward AM, Cox MJ, Fraser VJ. Attributable cost of catheter-associated bloodstream infections among intensive care patients in a nonteaching hospital. Crit Care Med. 2006;34:2084–9. [PubMed] [Google Scholar]

4. Blot SI, Depuydt P, Annemans L, et al. Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections. Clin Infect Dis. 2005;41:1591–8. [PubMed] [Google Scholar]

5. Renaud B, Brun-Buisson C. Outcomes of primary and catheter-related bacteremia. A cohort and case-control study in critically ill patients. Am J Respir Crit Care Med. 2001;163:1584–90. [PubMed] [Google Scholar]

6. Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin Proc. 2006;81:1159–71. [PubMed] [Google Scholar]

7. Yoo S, Ha M, Choi D, Pai H. Effectiveness of surveillance of central catheter-related bloodstream infection in an ICU in Korea. Infect Control Hosp Epidemiol. 2001;22:433–6. [PubMed] [Google Scholar]

8. Warren DK, Zack JE, Cox MJ, Cohen MM, Fraser VJ. An educational intervention to prevent catheter-associated bloodstream infections in a non-teeaching community medical center. Crit Care Med. 2003;31:1959–63. [PubMed] [Google Scholar]

9. Warren DK, Zack JE, Mayfield JL, et al. The effect of an education program on the incidence of central venous catheter-associated bloodstream infection in a medical ICU. Chest. 2004;126:1612–8. [PubMed] [Google Scholar]

10. Warren DK, Cosgrove SE, Diekema DJ, et al. A multicenter intervention to prevent catheter-associated bloodstream infections. Infect Control Hosp Epidemiol. 2006;27:662–9. [PubMed] [Google Scholar]

11. Higuera F, Rosenthal VD, Duarte P, Ruiz J, Franco G, Safdar N. The effect of process control on the incidence of central venous catheter-associated bloodstream infections and mortality in intensive care units in Mexico. Crit Care Med. 2005;33:2022–7. [PubMed] [Google Scholar]

12. Coopersmith CM, Rebmann TL, Zack JE, et al. Effect of an education program on decreasing catheter-related bloodstream infections in the surgical intensive care unit. Crit Care Med. 2002;30:59–64. [PubMed] [Google Scholar]

13. Coopersmith CM, Zack JE, Ward MR, et al. The impact of bedside behavior on catheter-related bacteremia in the intensive care unit. Arch Surg. 2004;139:131–6. [PubMed] [Google Scholar]

14. Sherertz RJ, Ely EW, Westbrook DM, et al. Education of physicians-in-training can decrease the risk for vascular catheter infection. Ann Intern Med. 2000;132:641–8. [PubMed] [Google Scholar]

15. Eggimann P, Harbarth S, Constantin MN, Touveneau S, Chevrolet JC, Pittet D. Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care. Lancet. 2000;355:1864–8. [PubMed] [Google Scholar]

16. Nehme AE. Nutritional support of the hospitalized patient. The team concept. JAMA. 1980;243:1906–8. [PubMed] [Google Scholar]

17. Soifer NE, Borzak S, Edlin BR, Weinstein RA. Prevention of peripheral venous catheter complications with an intravenous therapy team: a randomized controlled trial. Arch Intern Med. 1998;158:473–7. [PubMed] [Google Scholar]

18. Tomford JW, Hershey CO, McLaren CE, Porter DK, Cohen DI. Intravenous therapy team and peripheral venous catheter-associated complications. A prospective controlled study. Arch Intern Med. 1984;144:1191–4. [PubMed] [Google Scholar]

19. Scalley RD, Van CS, Cochran RS. The impact of an i.v. team on the occurrence of intravenous-related phlebitis. A 30-month study. J Intraven Nurs. 1992;15:100–9. [PubMed] [Google Scholar]

20. Palefski SS, Stoddard GJ. The infusion nurse and patient complication rates of peripheral-short catheters. A prospective evaluation. J Intraven Nurs. 2001;24:113–23. [PubMed] [Google Scholar]

21. Miller JM, Goetz AM, Squier C, Muder RR. Reduction in nosocomial intravenous device-related bacteremias after institution of an intravenous therapy team. J Intraven Nurs. 1996;19:103–6. [PubMed] [Google Scholar]

22. Hunter MR. Development of a Vascular Access Team in an acute care setting. J Infus Nurs. 2003;26:86–91. [PubMed] [Google Scholar]

23. Hawes ML. A proactive approach to combating venous depletion in the hospital setting. J Infus Nurs. 2007;30:33–44. [PubMed] [Google Scholar]

24. Brunelle D. Impact of a dedicated infusion therapy team on the reduction of catheter-related nosocomial infections. J Infus Nurs. 2003;26:362–6. [PubMed] [Google Scholar]

25. Bosma TL, Jewesson PJ. An infusion program resource nurse consult service: our experience in a major Canadian teaching hospital. J Infus Nurs. 2002;25:310–5. [PubMed] [Google Scholar]

26. Pierce CA, Baker JJ. A nursing process model: quantifying infusion therapy resource consumption. J Infus Nurs. 2004;27:232–44. [PubMed] [Google Scholar]

27. Tomford JW, Hershey CO. The i.v. therapy team: impact on patient care and costs of hospitalization. NITA. 1985;8:387–9. [PubMed] [Google Scholar]

28. Davis D, O'Brien MA, Freemantle N, Wolf FM, Mazmanian P, Taylor-Vaisey A. Impact of formal continuing medical education: do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes? JAMA. 1999;282:867–74. [PubMed] [Google Scholar]

29. Alonso-Echanove J, Edwards JR, Richards MJ, et al. Effect of nurse staffing and antimicrobial-impregnated central venous catheters on the risk for bloodstream infections in intensive care units. Infect Control Hosp Epidemiol. 2003;24:916–25. [PubMed] [Google Scholar]

30. Fridkin SK, Pear SM, Williamson TH, Galgiani JN, Jarvis WR. The role of understaffing in central venous catheter-associated bloodstream infections. Infect Control Hosp Epidemiol. 1996;17:150–8. [PubMed] [Google Scholar]

31. Robert J, Fridkin SK, Blumberg HM, et al. The influence of the composition of the nursing staff on primary bloodstream infection rates in a surgical intensive care unit. Infect Control Hosp Epidemiol. 2000;21:12–7. [PubMed] [Google Scholar]

32. Maki DG, Goldman DA, Rhame FS. Infection control in intravenous therapy. Ann Intern Med. 1973;79:867–87. [PubMed] [Google Scholar]

33. Band JD, Maki DG. Steel needles used for intravenous therapy. Morbidity in patients with hematologic malignancy. Arch Intern Med. 1980;140:31–4. [PubMed] [Google Scholar]

34. Tully JL, Friedland GH, Baldini LM, Goldmann DA. Complications of intravenous therapy with steel needles and Teflon catheters. A comparative study. Am J Med. 1981;70:702–6. [PubMed] [Google Scholar]

35. Ryder MA. Peripheral access options. Surg Oncol Clin N Am. 1995;4:395–427. [PubMed] [Google Scholar]

36. Maki DG, Ringer M. Risk factors for infusion-related phlebitis with small peripheral venous catheters. A randomized controlled trial. Ann Intern Med. 1991;114:845–54. [PubMed] [Google Scholar]

37. Mermel LA, McCormick RD, Springman SR, Maki DG. The pathogenesis and epidemiology of catheter-related infection with pulmonary artery Swan-Ganz catheters: a prospective study utilizing molecular subtyping. Am J Med. 1991;91:197S–205. [PubMed] [Google Scholar]

38. Parienti JJ, Thirion M, Megarbane B, et al. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial. JAMA. 2008;299:2413–22. [PubMed] [Google Scholar]

39. Moretti EW, Ofstead CL, Kristy RM, Wetzler HP. Impact of central venous catheter type and methods on catheter-related colonization and bacteraemia. J Hosp Infect. 2005;61:139–45. [PubMed] [Google Scholar]

40. Nagashima G, Kikuchi T, Tsuyuzaki H, et al. To reduce catheter-related bloodstream infections: is the subclavian route better than the jugular route for central venous catheterization? J Infect Chemother. 2006;12:363–5. [PubMed] [Google Scholar]

41. Ruesch S, Walder B, Tramer MR. Complications of central venous catheters: internal jugular versus subclavian access–a systematic review. Crit Care Med. 2002;30:454–60. [PubMed] [Google Scholar]

42. Sadoyama G, Gontijo Filho PP. Comparison between the jugular and subclavian vein as insertion site for central venous catheters: microbiological aspects and risk factors for colonization and infection. Braz J Infect Dis. 2003;7:142–8. [PubMed] [Google Scholar]

43. Heard SO, Wagle M, Vijayakumar E, et al. Influence of triple-lumen central venous catheters coated with chlorhexidine and silver sulfadiazine on the incidence of catheter-related bacteremia. Arch Intern Med. 1998;158:81–7. [PubMed] [Google Scholar]

44. Richet H, Hubert B, Nitemberg G, et al. Prospective multicenter study of vascular-catheter-related complications and risk factors for positive central-catheter cultures in intensive care unit patients. J Clin Microbiol. 1990;28:2520–5. [PMC free article] [PubMed] [Google Scholar]

45. Safdar N, Kluger DM, Maki DG. A review of risk factors for catheter-related bloodstream infection caused by percutaneously inserted, noncuffed central venous catheters: implications for preventive strategies. Medicine (Baltimore) 2002;81:466–79. [PubMed] [Google Scholar]

46. Lorente L, Jimenez A, Iribarren JL, Jimenez JJ, Martin MM, Mora ML. The micro-organism responsible for central venous catheter related bloodstream infection depends on catheter site. Intensive Care Med. 2006;32:1449–50. [PubMed] [Google Scholar]

47. Traore O, Liotier J, Souweine B. Prospective study of arterial and central venous catheter colonization and of arterial- and central venous catheter-related bacteremia in intensive care units. Crit Care Med. 2005;33:1276–80. [PubMed] [Google Scholar]

48. Joynt GM, Kew J, Gomersall CD, Leung VY, Liu EK. Deep venous thrombosis caused by femoral venous catheters in critically ill adult patients. Chest. 2000;117:178–83. [PubMed] [Google Scholar]

49. Mian NZ, Bayly R, Schreck DM, Besserman EB, Richmand D. Incidence of deep venous thrombosis associated with femoral venous catheterization. Acad Emerg Med. 1997;4:1118–21. [PubMed] [Google Scholar]

50. Merrer J, De Jonghe B, Golliot F, et al. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. JAMA. 2001;286:700–7. [PubMed] [Google Scholar]

51. Goetz AM, Wagener MM, Miller JM, Muder RR. Risk of infection due to central venous catheters: effect of site of placement and catheter type. Infect Control Hosp Epidemiol. 1998;19:842–5. [PubMed] [Google Scholar]

52. Robinson JF, Robinson WA, Cohn A, Garg K, Armstrong JD. 2nd. Perforation of the great vessels during central venous line placement. Arch Intern Med. 1995;155:1225–8. [PubMed] [Google Scholar]

53. Trottier SJ, Veremakis C, O'Brien J, Auer AI. Femoral deep vein thrombosis associated with central venous catheterization: results from a prospective, randomized trial. Crit Care Med. 1995;23:52–9. [PubMed] [Google Scholar]

54. Lorente L, Henry C, Martin MM, Jimenez A, Mora ML. Central venous catheter-related infection in a prospective and observational study of 2,595 catheters. Crit Care. 2005;9:R631–5. [PMC free article] [PubMed] [Google Scholar]

55. Schillinger F, Schillinger D, Montagnac R, Milcent T. Post catheterisation vein stenosis in haemodialysis: comparative angiographic study of 50 subclavian and 50 internal jugular accesses. Nephrol Dial Transplant. 1991;6:722–4. [PubMed] [Google Scholar]

56. Cimochowski GE, Worley E, Rutherford WE, Sartain J, Blondin J, Harter H. Superiority of the internal jugular over the subclavian access for temporary dialysis. Nephron. 1990;54:154–61. [PubMed] [Google Scholar]

57. Barrett N, Spencer S, McIvor J, Brown EA. Subclavian stenosis: a major complication of subclavian dialysis catheters. Nephrol Dial Transplant. 1988;3:423–5. [PubMed] [Google Scholar]

58. Trerotola SO, Kuhn-Fulton J, Johnson MS, Shah H, Ambrosius WT, Kneebone PH. Tunneled infusion catheters: increased incidence of symptomatic venous thrombosis after subclavian versus internal jugular venous access. Radiology. 2000;217:89–93. [PubMed] [Google Scholar]

59. National Kidney Foundation. III. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: update 2000. Am J Kidney Dis. 2001;37:S137–81. [PubMed] [Google Scholar]

60. Hind D, Calvert N, McWilliams R, et al. Ultrasonic locating devices for central venous cannulation: meta-analysis. BMJ. 2003;327:361. [PMC free article] [PubMed] [Google Scholar]

61. Randolph AG, Cook DJ, Gonzales CA, Pribble CG. Ultrasound guidance for placement of central venous catheters: a meta-analysis of the literature. Crit Care Med. 1996;24:2053–8. [PubMed] [Google Scholar]

62. Froehlich CD, Rigby MR, Rosenberg ES, et al. Ultrasound-guided central venous catheter placement decreases complications and decreases placement attempts compared with the landmark technique in patients in a pediatric intensive care unit. Crit Care Med. 2009;37:1090–6. [PubMed] [Google Scholar]

63. Lamperti M, Caldiroli D, Cortellazzi P, et al. Safety and efficacy of ultrasound assistance during internal jugular vein cannulation in neurosurgical infants. Intensive Care Med. 2008;34:2100–5. [PubMed] [Google Scholar]

64. Schweickert WD, Herlitz J, Pohlman AS, Gehlbach BK, Hall JB, Kress JP. A randomized, controlled trial evaluating postinsertion neck ultrasound in peripherally inserted central catheter procedures. Crit Care Med. 2009;37:1217–21. [PubMed] [Google Scholar]

65. Clark-Christoff N, Watters VA, Sparks W, Snyder P, Grant JP. Use of triple-lumen subclavian catheters for administration of total parenteral nutrition. JPEN J Parenter Enteral Nutr. 1992;16:403–7. [PubMed] [Google Scholar]

66. Early TF, Gregory RT, Wheeler JR, Snyder SO, Jr., Gayle RG. Increased infection rate in double-lumen versus single-lumen Hickman catheters in cancer patients. South Med J. 1990;83:34–6. [PubMed] [Google Scholar]

67. Hilton E, Haslett TM, Borenstein MT, Tucci V, Isenberg HD, Singer C. Central catheter infections: single- versus triple-lumen catheters. Influence of guide wires on infection rates when used for replacement of catheters. Am J Med. 1988;84:667–72. [PubMed] [Google Scholar]

68. Yeung C, May J, Hughes R. Infection rate for single lumen v triple lumen subclavian catheters. Infect Control Hosp Epidemiol. 1988;9:154–8. [PubMed] [Google Scholar]

69. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med. 2006;355:2725–32. [PubMed] [Google Scholar]

70. Berenholtz SM, Pronovost PJ, Lipsett PA, et al. Eliminating catheter-related bloodstream infections in the intensive care unit. Crit Care Med. 2004;32:2014–20. [PubMed] [Google Scholar]

71. Lederle FA, Parenti CM, Berskow LC, Ellingson KJ. The idle intravenous catheter. Ann Intern Med. 1992;116:737–8. [PubMed] [Google Scholar]

72. Parenti CM, Lederle FA, Impola CL, Peterson LR. Reduction of unnecessary intravenous catheter use. Internal medicine house staff participate in a successful quality improvement project. Arch Intern Med. 1994;154:1829–32. [PubMed] [Google Scholar]

73. Abi-Said D, Raad I, Umphrey J, et al. Infusion therapy team and dressing changes of central venous catheters. Infect Control Hosp Epidemiol. 1999;20:101–5. [PubMed] [Google Scholar]

74. Capdevila JA, Segarra A, Pahissa A. Catheter-related bacteremia in patients undergoing hemodialysis. Ann Intern Med. 1998;128:600. [PubMed] [Google Scholar]

75. Mermel LA, Maki DG. Infectious complications of Swan-Ganz pulmonary artery catheters. Pathogenesis, epidemiology, prevention, and management. Am J Respir Crit Care Med. 1994;149:1020–36. [PubMed] [Google Scholar]

76. Raad II, Hohn DC, Gilbreath BJ, et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol. 1994;15:231–8. [PubMed] [Google Scholar]

77. Boyce JM, Pittet D. Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol. 2002;23:S3–40. [PubMed] [Google Scholar]

78. Bischoff WE, Reynolds TM, Sessler CN, Edmond MB, Wenzel RP. Handwashing compliance by health care workers: the impact of introducing an accessible, alcohol-based hand antiseptic. Arch Intern Med. 2000;160:1017–21. [PubMed] [Google Scholar]

79. Pittet D, Dharan S, Touveneau S, Sauvan V, Perneger TV. Bacterial contamination of the hands of hospital staff during routine patient care. Arch Intern Med. 1999;159:821–6. [PubMed] [Google Scholar]

80. Carrer S, Bocchi A, Bortolotti M, et al. Effect of different sterile barrier precautions and central venous catheter dressing on the skin colonization around the insertion site. Minerva Anestesiol. 2005;71:197–206. [PubMed] [Google Scholar]

81. Cohen Y, Fosse JP, Karoubi P, et al. The "hands-off" catheter and the prevention of systemic infections associated with pulmonary artery catheter: a prospective study. Am J Respir Crit Care Med. 1998;157:284–7. [PubMed] [Google Scholar]

82. Maki DG, Ringer M, Alvarado CJ. Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet. 1991;338:339–43. [PubMed] [Google Scholar]

83. Mimoz O, Pieroni L, Lawrence C, et al. Prospective, randomized trial of two antiseptic solutions for prevention of central venous or arterial catheter colonization and infection in intensive care unit patients. Crit Care Med. 1996;24:1818–23. [PubMed] [Google Scholar]

84. Maki DG, Stolz SS, Wheeler S, Mermel LA. A prospective, randomized trial of gauze and two polyurethane dressings for site care of pulmonary artery catheters: implications for catheter management. Crit Care Med. 1994;22:1729–37. [PubMed] [Google Scholar]

85. Bijma R, Girbes AR, Kleijer DJ, Zwaveling JH. Preventing central venous catheter-related infection in a surgical intensive-care unit. Infect Control Hosp Epidemiol. 1999;20:618–20. [PubMed] [Google Scholar]

86. Madeo M, Martin CR, Turner C, Kirkby V, Thompson DR. A randomized trial comparing Arglaes (a transparent dressing containing silver ions) to Tegaderm (a transparent polyurethane dressing) for dressing peripheral arterial catheters and central vascular catheters. Intensive Crit Care Nurs. 1998;14:187–91. [PubMed] [Google Scholar]

87. Rasero L, Degl'Innocenti M, Mocali M, et al. Comparison of two different time interval protocols for central venous catheter dressing in bone marrow transplant patients: results of a randomized, multicenter study. The Italian Nurse Bone Marrow Transplant Group (GITMO) Haematologica. 2000;85:275–9. [PubMed] [Google Scholar]

88. Zakrzewska-Bode A, Muytjens HL, Liem KD, Hoogkamp-Korstanje JA. Mupirocin resistance in coagulase-negative staphylococci, after topical prophylaxis for the reduction of colonization of central venous catheters. J Hosp Infect. 1995;31:189–93. [PubMed] [Google Scholar]

89. Flowers RH, Schwenzer KJ, Kopel RF, Fisch MJ, Tucker SI, Farr BM. Efficacy of an attachable subcutaneous cuff for the prevention of intravascular catheter-related infection. A randomized, controlled trial. JAMA. 1989;261:878–83. [PubMed] [Google Scholar]

90. Robbins J, Cromwell P, Korones DN. Swimming and central venous catheter-related infections in the child with cancer. J Pediatr Oncol Nurs. 1999;16:51–6. [PubMed] [Google Scholar]

91. Howell PB, Walters PE, Donowitz GR, Farr BM. Risk factors for infection of adult patients with cancer who have tunnelled central venous catheters. Cancer. 1995;75:1367–75. [PubMed] [Google Scholar]

92. Ivy DD, Calderbank M, Wagner BD, et al. Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension. Infect Control Hosp Epidemiol. 2009;30:823–9. [PMC free article] [PubMed] [Google Scholar]

93. Timsit JF, Schwebel C, Bouadma L, et al. Chlorhexidine-impregnated sponges and less frequent dressing changes for prevention of catheter-related infections in critically ill adults: a randomized controlled trial. JAMA. 2009;301:1231–41. [PubMed] [Google Scholar]

94. Rao SP, Oreopoulos DG. Unusual complications of a polyurethane PD catheter. Perit Dial Int. 1997;17:410–2. [PubMed] [Google Scholar]

95. Riu S, Ruiz CG, Martinez-Vea A, Peralta C, Oliver JA. Spontaneous rupture of polyurethane peritoneal catheter. A possible deleterious effect of mupirocin ointment. Nephrol Dial Transplant. 1998;13:1870–1. [PubMed] [Google Scholar]

96. Garland JS, Alex CP, Mueller CD, et al. A randomized trial comparing povidone-iodine to a chlorhexidine gluconate-impregnated dressing for prevention of central venous catheter infections in neonates. Pediatrics. 2001;107:1431–6. [PubMed] [Google Scholar]

97. Ho KM, Litton E. Use of chlorhexidine-impregnated dressing to prevent vascular and epidural catheter colonization and infection: a meta-analysis. J Antimicrob Chemother. 2006;58:281–7. [PubMed] [Google Scholar]

98. Levy I, Katz J, Solter E, et al. Chlorhexidine-impregnated dressing for prevention of colonization of central venous catheters in infants and children: a randomized controlled study. Pediatr Infect Dis J. 2005;24:676–9. [PubMed] [Google Scholar]

99. Lorenzen AN, Itkin DJ. Surveillance of infection in home care. Am J Infect Control. 1992;20:326–9. [PubMed] [Google Scholar]

100. White MC. Infections and infection risks in home care settings. Infect Control Hosp Epidemiol. 1992;13:535–9. [PubMed] [Google Scholar]

101. White MC, Ragland KE. Surveillance of intravenous catheter-related infections among home care clients. Am J Infect Control. 1994;22:231–5. [PubMed] [Google Scholar]

102. Bleasdale SC, Trick WE, Gonzalez IM, Lyles RD, Hayden MK, Weinstein RA. Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients. Arch Intern Med. 2007;167:2073–9. [PubMed] [Google Scholar]

103. Munoz-Price LS, Hota B, Stemer A, Weinstein RA. Prevention of bloodstream infections by use of daily chlorhexidine baths for patients at a long-term acute care hospital. Infect Control Hosp Epidemiol. 2009;30:1031–5. [PubMed] [Google Scholar]

104. Popovich KJ, Hota B, Hayes R, Weinstein RA, Hayden MK. Effectiveness of routine patient cleansing with chlorhexidine gluconate for infection prevention in the medical intensive care unit. Infect Control Hosp Epidemiol. 2009;30:959–63. [PubMed] [Google Scholar]

105. Yamamoto AJ, Solomon JA, Soulen MC, et al. Sutureless securement device reduces complications of peripherally inserted central venous catheters. J Vasc Interv Radiol. 2002;13:77–81. [PubMed] [Google Scholar]

106. Brun-Buisson C, Doyon F, Sollet JP, Cochard JF, Cohen Y, Nitenberg G. Prevention of intravascular catheter-related infection with newer chlorhexidine-silver sulfadiazine-coated catheters: a randomized controlled trial. Intensive Care Med. 2004;30:837–43. [PubMed] [Google Scholar]

107. Ostendorf T, Meinhold A, Harter C, et al. Chlorhexidine and silver-sulfadiazine coated central venous catheters in haematological patients–a double-blind, randomised, prospective, controlled trial. Support Care Cancer. 2005;13:993–1000. [PubMed] [Google Scholar]

108. Rupp ME, Lisco SJ, Lipsett PA, et al. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial. Ann Intern Med. 2005;143:570–80. [PubMed] [Google Scholar]

109. Darouiche RO, Raad II, Heard SO, et al. A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group. N Engl J Med. 1999;340:1–8. [PubMed] [Google Scholar]

110. Raad I, Darouiche R, Dupuis J, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med. 1997;127:267–74. [PubMed] [Google Scholar]

111. Hanna H, Benjamin R, Chatzinikolaou I, et al. Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. J Clin Oncol. 2004;22:3163–71. [PubMed] [Google Scholar]

112. Bhutta A, Gilliam C, Honeycutt M, et al. Reduction of bloodstream infections associated with catheters in paediatric intensive care unit: stepwise approach. BMJ. 2007;334:362–5. [PMC free article] [PubMed] [Google Scholar]

113. Chelliah A, Heydon KH, Zaoutis TE, et al. Observational trial of antibiotic-coated central venous catheters in critically ill pediatric patients. Pediatr Infect Dis J. 2007;26:816–20. [PubMed] [Google Scholar]

114. van de Wetering MD, van Woensel JBM. Prophylactic antibiotics for preventing early central venous catheter Gram positive infections in oncology patients. Cochrane Database of Systematic Reviews. 2007 Issue 1. Art. No.: CD003295. DOI: 10.1002/14651858.CD003295.pub2. [PubMed] [Google Scholar]

115. Maki DG, Band JD. A comparative study of polyantibiotic and iodophorointments in prevention of vascular catheter-related infection. Am J Med. 1981;70:739–44. [PubMed] [Google Scholar]

116. Fukunaga A, Naritaka H, Fukaya R, Tabuse M, Nakamura T. Povidone-iodine ointment and gauze dressings associated with reduced catheter-related infection in seriously ill neurosurgical patients. Infect Control Hosp Epidemiol. 2004;25:696–8. [PubMed] [Google Scholar]

117. Johnson DW, MacGinley R, Kay TD, et al. A randomized controlled trial of topical exit site mupirocin application in patients with tunnelled, cuffed haemodialysis catheters. Nephrol Dial Transplant. 2002;17:1802–7. [PubMed] [Google Scholar]

118. Fong IW. Prevention of haemodialysis and peritoneal dialysis catheter related infection by topical povidone-iodine. Postgrad Med J. 1993;69(Suppl 3):S15–7. [PubMed] [Google Scholar]

119. Levin A, Mason AJ, Jindal KK, Fong IW, Goldstein MB. Prevention of hemodialysis subclavian vein catheter infections by topical povidone-iodine. Kidney Int. 1991;40:934–8. [PubMed] [Google Scholar]

120. Schwartz C, Henrickson KJ, Roghmann K, Powell K. Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms. J Clin Oncol. 1990;8:1591–7. [PubMed] [Google Scholar]

121. Rackoff WR, Weiman M, Jakobowski D, et al. A randomized, controlled trial of the efficacy of a heparin and vancomycin solution in preventing central venous catheter infections in children. J Pediatr. 1995;127:147–51. [PubMed] [Google Scholar]

122. Carratala J, Niubo J, Fernandez-Sevilla A, et al. Randomized, double-blind trial of an antibiotic-lock technique for prevention of gram-positive central venous catheter-related infection in neutropenic patients with cancer. Antimicrob Agents Chemother. 1999;43:2200–4. [PMC free article] [PubMed] [Google Scholar]

123. Jurewitsch B, Lee T, Park J, Jeejeebhoy K. Taurolidine 2% as an antimicrobial lock solution for prevention of recurrent catheter-related bloodstream infections. J Parenter Enteral Nutr. 1998;22:242–4. [PubMed] [Google Scholar]

124. Henrickson KJ, Axtell RA, Hoover SM, et al. Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solution: a randomized, multicenter, double-blind trial. J Clin Oncol. 2000;18:1269–78. [PubMed] [Google Scholar]

125. Garland JS, Alex CP, Henrickson KJ, McAuliffe TL, Maki DG. A vancomycin-heparin lock solution for prevention of nosocomial bloodstream infection in critically ill neonates with peripherally inserted central venous catheters: a prospective, randomized trial. Pediatrics. 2005;116:e198–205. [PubMed] [Google Scholar]

126. Daghistani D, Horn M, Rodriguez Z, Schoenike S, Toledano S. Prevention of indwelling central venous catheter sepsis. Med Pediatr Oncol. 1996;26:405–8. [PubMed] [Google Scholar]

127. Barriga FJ, Varas M, Potin M, et al. Efficacy of a vancomycin solution to prevent bacteremia associated with an indwelling central venous catheter in neutropenic and non-neutropenic cancer patients. Med Pediatr Oncol. 1997;28:196–200. [PubMed] [Google Scholar]

128. Dogra GK, Herson H, Hutchison B, et al. Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: a randomized controlled study. J Am Soc Nephrol. 2002;13:2133–9. [PubMed] [Google Scholar]

129. Allon M. Prophylaxis against dialysis catheter-related bacteremia with a novel antimicrobial lock solution. Clin Infect Dis. 2003;36:1539–44. [PubMed] [Google Scholar]

130. Elhassan NO, Stevens TP, Gigliotti F, Hardy DJ, Cole CA, Sinkin RA. Vancomycin usage in central venous catheters in a neonatal intensive care unit. Pediatr Infect Dis J. 2004;23:201–6. [PubMed] [Google Scholar]

131. McIntyre CW, Hulme LJ, Taal M, Fluck RJ. Locking of tunneled hemodialysis catheters with gentamicin and heparin. Kidney Int. 2004;66:801–5. [PubMed] [Google Scholar]

132. Betjes MG, van Agteren M. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrol Dial Transplant. 2004;19:1546–1. [PubMed] [Google Scholar]

133. Weijmer MC, van den Dorpel MA, Van de Ven PJ, et al. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol. 2005;16:2769–77. [PubMed] [Google Scholar]

134. Bleyer AJ, Mason L, Russell G, Raad II, Sherertz RJ. A randomized, controlled trial of a new vascular catheter flush solution (minocycline-EDTA) in temporary hemodialysis access. Infect Control Hosp Epidemiol. 2005;26:520–4. [PubMed] [Google Scholar]

135. Kim SH, Song KI, Chang JW, et al. Prevention of uncuffed hemodialysis catheter-related bacteremia using an antibiotic lock technique: a prospective, randomized clinical trial. Kidney Int. 2006;69:161–4. [PubMed] [Google Scholar]

136. Al-Hwiesh AK, Abdul-Rahman IS. Successful prevention of tunneled, central catheter infection by antibiotic lock therapy using vancomycin and gentamycin. Saudi J Kidney Dis Transpl. 2007;18:239–47. [PubMed] [Google Scholar]

137. Nori US, Manoharan A, Yee J, Besarab A. Comparison of low-dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter-related bacteremia. Am J Kidney Dis. 2006;48:596–605. [PubMed] [Google Scholar]

138. Saxena AK, Panhotra BR, Sundaram DS, et al. Tunneled catheters' outcome optimization among diabetics on dialysis through antibiotic-lock placement. Kidney Int. 2006;70:1629–35. [PubMed] [Google Scholar]

139. Randolph AG, Cook DJ, Gonzales CA, Andrew M. Benefit of heparin in central venous and pulmonary artery catheters: a meta-analysis of randomized controlled trials. Chest. 1998;113:165–71. [PubMed] [Google Scholar]

140. Tager IB, Ginsberg MB, Ellis SE, et al. An epidemiologic study of the risks associated with peripheral intravenous catheters. Am J Epidemiol. 1983;118:839–51. [PubMed] [Google Scholar]

141. Lai KK. Safety of prolonging peripheral cannula and i.v. tubing use from 72 hours to 96 hours. Am J Infect Control. 1998;26:66–70. [PubMed] [Google Scholar]

142. Van Donk P, Rickard CM, McGrail MR, Doolan G. Routine replacement versus clinical monitoring of peripheral intravenous catheters in a regional hospital in the home program: a randomized controlled trial. Infect Control Hosp Epidemiol. 2009;30:915–7. [PubMed] [Google Scholar]

143. Webster J, Clarke S, Paterson D, et al. Routine care of peripheral intravenous catheters versus clinically indicated replacement: randomised controlled trial. BMJ. 2008;337:a339. [PMC free article] [PubMed] [Google Scholar]

144. Webster J, Osborne S, Rickard C, Hall J. Clinically-indicated replacement versus routine replacement of peripheral venous catheters. Cochrane Database Syst Rev. 2010;3 CD007798. [PubMed] [Google Scholar]

145. Boo NY, Wong NC, Zulkifli SS, Lye MS. Risk factors associated with umbilical vascular catheter-associated thrombosis in newborn infants. J Paediatr Child Health. 1999;35:460–5. [PubMed] [Google Scholar]

146. Garland JS, Buck RK, Maloney P, et al. Comparison of 10% povidone-iodine and 0.5% chlorhexidine gluconate for the prevention of peripheral intravenous catheter colonization in neonates: a prospective trial. Pediatr Infect Dis J. 1995;14:510–6. [PubMed] [Google Scholar]

147. Krauss AN, Albert RF, Kannan MM. Contamination of umbilical catheters in the newborn infant. J Pediatr. 1970;77:965–9. [PubMed] [Google Scholar]

148. Landers S, Moise AA, Fraley JK, Smith EO, Baker CJ. Factors associated with umbilical catheter-related sepsis in neonates. Am J Dis Child. 1991;145:675–80. [PubMed] [Google Scholar]

149. Cronin WA, Germanson TP, Donowitz LG. Intravascular catheter colonization and related bloodstream infection in critically ill neonates. Infect Control Hosp Epidemiol. 1990;11:301–8. [PubMed] [Google Scholar]

150. Miller KL, Coen PE, White WJ, Hurst WJ, Achey BE, Lang CM. Effectiveness of skin absorption of tincture of I in blocking radioiodine from the human thyroid gland. Health Phys. 1989;56:911–4. [PubMed] [Google Scholar]

151. Ankola PA, Atakent YS. Effect of adding heparin in very low concentration to the infusate to prolong the patency of umbilical artery catheters. Am J Perinatol. 1993;10:229–32. [PubMed] [Google Scholar]

152. David RJ, Merten DF, Anderson JC, Gross S. Prevention of umbilical artery catheter clots with heparinized infusates. Dev Pharmacol Ther. 1981;2:117–26. [PubMed] [Google Scholar]

153. Horgan MJ, Bartoletti A, Polansky S, Peters JC, Manning TJ, Lamont BM. Effect of heparin infusates in umbilical arterial catheters on frequency of thrombotic complications. J Pediatr. 1987;111:774–8. [PubMed] [Google Scholar]

154. Fletcher MA, Brown DR, Landers S, Seguin J. Umbilical arterial catheter use: report of an audit conducted by the Study Group for Complications of Perinatal Care. Am J Perinatol. 1994;11:94–9. [PubMed] [Google Scholar]

155. Seguin J, Fletcher MA, Landers S, Brown D, Macpherson T. Umbilical venous catheterizations: audit by the Study Group for Complications of Perinatal Care. Am J Perinatol. 1994;11:67–70. [PubMed] [Google Scholar]

156. Loisel DB, Smith MM, MacDonald MG, Martin GR. Intravenous access in newborn infants: impact of extended umbilical venous catheter use on requirement for peripheral venous lines. J Perinatol. 1996;16:461–6. [PubMed] [Google Scholar]

157. Martin C, Saux P, Papazian L, Gouin F. Long-term arterial cannulation in ICU patients using the radial artery or dorsalis pedis artery. Chest. 2001;119:901–6. [PubMed] [Google Scholar]

158. Koh DB, Gowardman JR, Rickard CM, Robertson IK, Brown A. Prospective study of peripheral arterial catheter infection and comparison with concurrently sited central venous catheters. Crit Care Med. 2008;36:397–402. [PubMed] [Google Scholar]

159. Rijnders BJ, Van Wijngaerden E, Wilmer A, Peetermans WE. Use of full sterile barrier precautions during insertion of arterial catheters: a randomized trial. Clin Infect Dis. 2003;36:743–8. [PubMed] [Google Scholar]

160. Donowitz LG, Marsik FJ, Hoyt JW, Wenzel RP. Serratia marcescens bacteremia from contaminated pressure transducers. JAMA. 1979;242:1749–51. [PubMed] [Google Scholar]

161. Luskin RL, Weinstein RA, Nathan C, Chamberlin WH, Kabins SA. Extended use of disposable pressure transducers. A bacteriologic evaluation. JAMA. 1986;255:916–20. [PubMed] [Google Scholar]

162. Maki DG, Hassemer CA. Endemic rate of fluid contamination and related septicemia in arterial pressure monitoring. Am J Med. 1981;70:733–8. [PubMed] [Google Scholar]

163. Mermel LA, Maki DG. Epidemic bloodstream infections from hemodynamic pressure monitoring: signs of the times. Infect Control Hosp Epidemiol. 1989;10:47–53. [PubMed] [Google Scholar]

164. Tenold R, Priano L, Kim K, Rourke B, Marrone T. Infection potential of nondisposable pressure transducers prepared prior to use. Crit Care Med. 1987;15:582–3. [PubMed] [Google Scholar]

165. Eyer S, Brummitt C, Crossley K, Siegel R, Cerra F. Catheter-related sepsis: prospective, randomized study of three methods of long-term catheter maintenance. Crit Care Med. 1990;18:1073–9. [PubMed] [Google Scholar]

166. Raad I, Umphrey J, Khan A, Truett LJ, Bodey GP. The duration of placement as a predictor of peripheral and pulmonary arterial catheter infections. J Hosp Infect. 1993;23:17–26. [PubMed] [Google Scholar]

167. Thomas F, Burke JP, Parker J, et al. The risk of infection related to radial vs femoral sites for arterial catheterization. Crit Care Med. 1983;11:807–12. [PubMed] [Google Scholar]

168. Leroy O, Billiau V, Beuscart C, et al. Nosocomial infections associated with long-term radial artery cannulation. Intensive Care Med. 1989;15:241–6. [PubMed] [Google Scholar]

169. Fisher MC, Long SS, Roberts EM, Dunn JM, Balsara RK. Pseudomonas maltophilia bacteremia in children undergoing open heart surgery. JAMA. 1981;246:1571–4. [PubMed] [Google Scholar]

170. Stamm WE, Colella JJ, Anderson RL, Dixon RE. Indwelling arterial catheters as a source of nosocomial bacteremia. An outbreak caused by Flavobacterium Species. N Engl J Med. 1975;292:1099–102. [PubMed] [Google Scholar]

171. Weinstein RA, Emori TG, Anderson RL, Stamm WE. Pressure transducers as a source of bacteremia after open heart surgery. Report of an outbreak and guidelines for prevention. Chest. 1976;69:338–44. [PubMed] [Google Scholar]

172. Shinozaki T, Deane RS, Mazuzan JE, Jr., Hamel AJ, Hazelton D. Bacterial contamination of arterial lines. A prospective study. JAMA. 1983;249:223–5. [PubMed] [Google Scholar]

173. Solomon SL, Alexander H, Eley JW, et al. Nosocomial fungemia in neonates associated with intravascular pressure-monitoring devices. Pediatr Infect Dis. 1986;5:680–5. [PubMed] [Google Scholar]

174. Weems JJ, Jr., Chamberland ME, Ward J, Willy M, Padhye AA, Solomon SL. Candida parapsilosis fungemia associated with parenteral nutrition and contaminated blood pressure transducers. J Clin Microbiol. 1987;25:1029–32. [PMC free article] [PubMed] [Google Scholar]

175. Villarino ME, Jarvis WR, O'Hara C, Bresnahan J, Clark N. Epidemic of Serratia marcescens bacteremia in a cardiac intensive care unit. J Clin Microbiol. 1989;27:2433–6. [PMC free article] [PubMed] [Google Scholar]

176. Beck-Sague CM, Jarvis WR, Brook JH, et al. Epidemic bacteremia due to Acinetobacter baumannii in five intensive care units. Am J Epidemiol. 1990;132:723–33. [PubMed] [Google Scholar]

177. Gillies D, Wallen MM, Morrison AL, Rankin K, Nagy SA, O'Riordan E. Optimal timing for intravenous administration set replacement. Cochrane Database of Systematic Reviews. 2005 Issue 4. Art. No.: CD003588. DOI: 10.1002/14651858.CD003588.pub2. [PubMed] [Google Scholar]

178. Sitges-Serra A, Linares J, Perez JL, Jaurrieta E, Lorente L. A randomized trial on the effect of tubing changes on hub contamination and catheter sepsis during parenteral nutrition. JPEN J Parenter Enteral Nutr. 1985;9:322–5. [PubMed] [Google Scholar]

179. Snydman DR, Donnelly-Reidy M, Perry LK, Martin WJ. Intravenous tubing containing burettes can be safely changed at 72 hour intervals. Infect Control. 1987;8:113–6. [PubMed] [Google Scholar]

180. Maki DG, Botticelli JT, LeRoy ML, Thielke TS. Prospective study of replacing administration sets for intravenous therapy at 48- vs 72-hour intervals. 72 hours is safe and cost-effective. JAMA. 1987;258:1777–81. [PubMed] [Google Scholar]

181. Josephson A, Gombert ME, Sierra MF, Karanfil LV, Tansino GF. The relationship between intravenous fluid contamination and the frequency of tubing replacement. Infect Control. 1985;6:367–70. [PubMed] [Google Scholar]

182. Melly MA, Meng HC, Schaffner W. Microbiol growth in lipid emulsions used in parenteral nutrition. Arch Surg. 1975;110:1479–81. [PubMed] [Google Scholar]

183. Mershon J, Nogami W, Williams JM, Yoder C, Eitzen HE, Lemons JA. Bacterial/fungal growth in a combined parenteral nutrition solution. JPEN J Parenter Enteral Nutr. 1986;10:498–502. [PubMed] [Google Scholar]

184. Gilbert M, Gallagher SC, Eads M, Elmore MF. Microbial growth patterns in a total parenteral nutrition formulation containing lipid emulsion. JPEN J Parenter Enteral Nutr. 1986;10:494–7. [PubMed] [Google Scholar]

185. Maki DG, Martin WT. Nationwide epidemic of septicemia caused by contaminated infusion products. IV. Growth of microbial pathogens in fluids for intravenous infusions. J Infect Dis. 1975;131:267–72. [PubMed] [Google Scholar]

186. Bennett SN, McNeil MM, Bland LA, et al. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. N Engl J Med. 1995;333:147–54. [PubMed] [Google Scholar]

187. Arduino MJ, Bland LA, Danzig LE, McAllister SK, Aguero SM. Microbiologic evaluation of needleless and needle-access devices. Am J Infect Control. 1997;25:377–80. [PubMed] [Google Scholar]

188. Brown JD, Moss HA, Elliott TS. The potential for catheter microbial contamination from a needleless connector. J Hosp Infect. 1997;36:181–9. [PubMed] [Google Scholar]

189. Cookson ST, Ihrig M, O'Mara EM, et al. Increased bloodstream infection rates in surgical patients associated with variation from recommended use and care following implementation of a needleless device. Infect Control Hosp Epidemiol. 1998;19:23–7. [PubMed] [Google Scholar]

190. Seymour VM, Dhallu TS, Moss HA, Tebbs SE, Elliot TS. A prospective clinical study to investigate the microbial contamination of a needleless connector. J Hosp Infect. 2000;45:165–8. [PubMed] [Google Scholar]

191. Luebke MA, Arduino MJ, Duda DL, et al. Comparison of the microbial barrier properties of a needleless and a conventional needle-based intravenous access system. Am J Infect Control. 1998;26:437–41. [PubMed] [Google Scholar]

192. McDonald LC, Banerjee SN, Jarvis WR. Line-associated bloodstream infections in pediatric intensive-care-unit patients associated with a needleless device and intermittent intravenous therapy. Infect Control Hosp Epidemiol. 1998;19:772–7. [PubMed] [Google Scholar]

193. Mendelson MH, Short LJ, Schechter CB, et al. Study of a needleless intermittent intravenous-access system for peripheral infusions: analysis of staff, patient, and institutional outcomes. Infect Control Hosp Epidemiol. 1998;19:401–6. [PubMed] [Google Scholar]

194. Do AN, Ray BJ, Banerjee SN, et al. Bloodstream infection associated with needleless device use and the importance of infection-control practices in the home health care setting. J Infect Dis. 1999;179:442–8. [PubMed] [Google Scholar]

195. Soothill JS, Bravery K, Ho A, Macqueen S, Collins J, Lock P. A fall in bloodstream infections followed a change to 2% chlorhexidine in 70% isopropanol for catheter connection antisepsis: a pediatric single center before/after study on a hemopoietic stem cell transplant ward. Am J Infect Control. 2009;37:626–30. [PubMed] [Google Scholar]

196. Casey AL, Burnell S, Whinn H, Worthington T, Faroqui MH, Elliott TS. A prospective clinical trial to evaluate the microbial barrier of a needleless connector. J Hosp Infect. 2007;65:212–8. [PubMed] [Google Scholar]

197. Rupp ME, Sholtz LA, Jourdan DR, et al. Outbreak of bloodstream infection temporally associated with the use of an intravascular needleless valve. Clin Infect Dis. 2007;44:1408–14. [PubMed] [Google Scholar]

198. Salgado CD, Chinnes L, Paczesny TH, Cantey JR. Increased rate of catheter-related bloodstream infection associated with use of a needleless mechanical valve device at a long-term acute care hospital. Infect Control Hosp Epidemiol. 2007;28:684–8. [PubMed] [Google Scholar]

199. Maragakis LL, Bradley KL, Song X, et al. Increased catheter-related bloodstream infection rates after the introduction of a new mechanical valve intravenous access port. Infect Control Hosp Epidemiol. 2006;27:67–70. [PubMed] [Google Scholar]

200. Field K, McFarlane C, Cheng AC, et al. Incidence of catheter-related bloodstream infection among patients with a needleless, mechanical valve-based intravenous connector in an Australian hematology-oncology unit. Infect Control Hosp Epidemiol. 2007;28:610–3. [PubMed] [Google Scholar]

201. Costello JM, Morrow DF, Graham DA, Potter-Bynoe G, Sandora TJ, Laussen PC. Systematic intervention to reduce central line-associated bloodstream infection rates in a pediatric cardiac intensive care unit. Pediatrics. 2008;121:915–23. [PubMed] [Google Scholar]

202. Frankel HL, Crede WB, Topal JE, Roumanis SA, Devlin MW, Foley AB. Use of corporate Six Sigma performance-improvement strategies to reduce incidence of catheter-related bloodstream infections in a surgical ICU. J Am Coll Surg. 2005;201:349–58. [PubMed] [Google Scholar]

203. Galpern D, Guerrero A, Tu A, Fahoum B, Wise L. Effectiveness of a central line bundle campaign on line-associated infections in the intensive care unit. Surgery. 2008;144:492–5. discussion 495. [PubMed] [Google Scholar]

204. McKee C, Berkowitz I, Cosgrove SE, et al. Reduction of catheter-associated bloodstream infections in pediatric patients: experimentation and reality. Pediatr Crit Care Med. 2008;9:40–6. [PubMed] [Google Scholar]

205. Pronovost PJ, Berenholtz SM, Goeschel CA. Improving the quality of measurement and evaluation in quality improvement efforts. Am J Med Qual. 2008;23:143–6. [PubMed] [Google Scholar]

206. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309–32. [PubMed] [Google Scholar]

207. Edwards JR, Peterson KD, Mu Y, et al. National Healthcare Safety Network (NHSN) report: data summary for 2006 through 2008, issued December 2009. Am J Infect Control. 2009;37:783–805. [PubMed] [Google Scholar]

208. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–17. [PubMed] [Google Scholar]

209. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41:848–54. [PubMed] [Google Scholar]

210. Burton DC, Edwards JR, Horan TC, Jernigan JA, Fridkin SK. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997–2007. JAMA. 2009;301:727–36. [PubMed] [Google Scholar]

211. Safdar N, Maki DG. The pathogenesis of catheter-related bloodstream infection with noncuffed short-term central venous catheters. Intensive Care Med. 2004;30:62–7. [PubMed] [Google Scholar]

212. Maki DG, Weise CE, Sarafin HW. A semiquantitative culture method for identifying intravenous-catheter-related infection. N Engl J Med. 1977;296:1305–9. [PubMed] [Google Scholar]

213. Raad I, Costerton W, Sabharwal U, Sacilowski M, Anaissie E, Bodey GP. Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis. 1993;168:400–7. [PubMed] [Google Scholar]

214. Dobbins BM, Kite P, Kindon A, McMahon MJ, Wilcox MH. DNA fingerprinting analysis of coagulase negative staphylococci implicated in catheter related bloodstream infections. J Clin Pathol. 2002;55:824–8. [PMC free article] [PubMed] [Google Scholar]

215. Anaissie E, Samonis G, Kontoyiannis D, et al. Role of catheter colonization and infrequent hematogenous seeding in catheter-related infections. Eur J Clin Microbiol Infect Dis. 1995;14:134–7. [PubMed] [Google Scholar]

216. Raad I, Hanna HA, Awad A, et al. Optimal frequency of changing intravenous administration sets: is it safe to prolong use beyond 72 hours? Infect Control Hosp Epidemiol. 2001;22:136–9. [PubMed] [Google Scholar]

217. Mehall JR, Saltzman DA, Jackson RJ, Smith SD. Fibrin sheath enhances central venous catheter infection. Crit Care Med. 2002;30:908–12. [PubMed] [Google Scholar]

218. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15:167–93. [PMC free article] [PubMed] [Google Scholar]

219. Hawser SP, Douglas LJ. Biofilm formation by Candida species on the surface of catheter materials in vitro. Infect Immun. 1994;62:915–21. [PMC free article] [PubMed] [Google Scholar]

220. Stillman RM, Soliman F, Garcia L, Sawyer PN. Etiology of catheter-associated sepsis. Correlation with thrombogenicity. Arch Surg. 1977;112:1497–9. [PubMed] [Google Scholar]

221. Raad II, Luna M, Khalil SA, Costerton JW, Lam C, Bodey GP. The relationship between the thrombotic and infectious complications of central venous catheters. JAMA. 1994;271:1014–6. [PubMed] [Google Scholar]

222. Herrmann M, Suchard SJ, Boxer LA, Waldvogel FA, Lew PD. Thrombospondin binds to Staphylococcus aureus and promotes staphylococcal adherence to surfaces. Infect Immun. 1991;59:279–88. [PMC free article] [PubMed] [Google Scholar]

223. Shanks RM, Sargent JL, Martinez RM, Graber ML, O'Toole GA. Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces. Nephrol Dial Transplant. 2006;21:2247–55. [PubMed] [Google Scholar]

224. Chatzinikolaou I, Zipf TF, Hanna H, et al. Minocycline-ethylenediaminetetraacetate lock solution for the prevention of implantable port infections in children with cancer. Clin Infect Dis. 2003;36:116–9. [PubMed] [Google Scholar]

225. McDevitt D, Francois P, Vaudaux P, Foster TJ. Identification of the ligand-binding domain of the surface-located fibrinogen receptor (clumping factor) of Staphylococcus aureus. Mol Microbiol. 1995;16:895–907. [PubMed] [Google Scholar]

226. Ni Eidhin D, Perkins S, Francois P, Vaudaux P, Hook M, Foster TJ. Clumping factor B (ClfB), a new surface-located fibrinogen-binding adhesin of Staphylococcus aureus. Mol Microbiol. 1998;30:245–57. [PubMed] [Google Scholar]

227. Mack D, Davies AP, Harris LG, Rohde H, Horstkotte MA, Knobloch JK. Microbial interactions in Staphylococcus epidermidis biofilms. Anal Bioanal Chem. 2007;387:399–408. [PubMed] [Google Scholar]

228. von Eiff C, Peters G, Heilmann C. Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect Dis. 2002;2:677–85. [PubMed] [Google Scholar]

229. Zhu Y, Weiss EC, Otto M, Fey PD, Smeltzer MS, Somerville GA. Staphylococcus aureus metabolism in a biofilm: the influence of arginine on polysaccharide intercellular adhesin synthesis, biofilm formation, and pathogenesis. Infect Immun. 2007;75:4219–26. [PMC free article] [PubMed] [Google Scholar]

230. Murga R, Miller JM, Donlan RM. Biofilm formation by gram-negative bacteria on central venous catheter connectors: effect of conditioning films in a laboratory model. J Clin Microbiol. 2001;39:2294–7. [PMC free article] [PubMed] [Google Scholar]

231. Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol. 2003;11:30–6. [PubMed] [Google Scholar]

233. Dunne WM, Jr., Burd EM. The effects of magnesium, calcium, EDTA, and pH on the in vitro adhesion of Staphylococcus epidermidis to plastic. Microbiol Immunol. 1992;36:1019–27. [PubMed] [Google Scholar]

234. Ozerdem Akpolat N, Elci S, Atmaca S, Akbayin H, Gul K. The effects of magnesium, calcium and EDTA on slime production by Staphylococcus epidermidis strains. Folia Microbiol (Praha) 2003;48:649–53. [PubMed] [Google Scholar]

235. Banin E, Brady KM, Greenberg EP. Chelator-induced dispersal and killing of Pseudomonas aeruginosa cells in a biofilm. Appl Environ Microbiol. 2006;72:2064–9. [PMC free article] [PubMed] [Google Scholar]

236. Donlan RM. Role of biofilms in antimicrobial resistance. ASAIO J. 2000;46:S47–52. [PubMed] [Google Scholar]

237. Farber BF, Kaplan MH, Clogston AG. Staphylococcus epidermidis extracted slime inhibits the antimicrobial action of glycopeptide antibiotics. J Infect Dis. 1990;161:37–40. [PubMed] [Google Scholar]

238. Branchini ML, Pfaller MA, Rhine-Chalberg J, Frempong T, Isenberg HD. Genotypic variation and slime production among blood and catheter isolates of Candida parapsilosis. J Clin Microbiol. 1994;32:452–6. [PMC free article] [PubMed] [Google Scholar]

239. Sanders RA, Sheldon GF. Septic complications of total parenteral nutrition. A five year experience. Am J Surg. 1976;132:214–20. [PubMed] [Google Scholar]

240. Ryan JA, Jr., Abel RM, Abbott WM, et al. Catheter complications in total parenteral nutrition. A prospective study of 200 consecutive patients. N Engl J Med. 1974;290:757–61. [PubMed] [Google Scholar]

241. Murphy LM, Lipman TO. Central venous catheter care in parenteral nutrition: a review. JPEN J Parenter Enteral Nutr. 1987;11:190–201. [PubMed] [Google Scholar]

242. Armstrong CW, Mayhall CG, Miller KB, et al. Prospective study of catheter replacement and other risk factors for infection of hyperalimentation catheters. J Infect Dis. 1986;154:808–16. [PubMed] [Google Scholar]

243. Garland JS, Dunne WM, Jr., Havens P, et al. Peripheral intravenous catheter complications in critically ill children: a prospective study. Pediatrics. 1992;89:1145–50. [PubMed] [Google Scholar]

244. Garland JS, Nelson DB, Cheah TE, Hennes HH, Johnson TM. Infectious complications during peripheral intravenous therapy with Teflon catheters: a prospective study. Pediatr Infect Dis J. 1987;6:918–21. [PubMed] [Google Scholar]

245. Breschan C, Platzer M, Jost R, Schaumberger F, Stettner H, Likar R. Comparison of catheter-related infection and tip colonization between internal jugular and subclavian central venous catheters in surgical neonates. Anesthesiology. 2007;107:946–53. [PubMed] [Google Scholar]

246. Deshpande KS, Hatem C, Ulrich HL, et al. The incidence of infectious complications of central venous catheters at the subclavian, internal jugular, and femoral sites in an intensive care unit population. Crit Care Med. 2005;33:13–20. discussion 234–5. [PubMed] [Google Scholar]

247. Durbec O, Viviand X, Potie F, Vialet R, Albanese J, Martin C. A prospective evaluation of the use of femoral venous catheters in critically ill adults. Crit Care Med. 1997;25:1986–9. [PubMed] [Google Scholar]

248. Venkataraman ST, Thompson AE, Orr RA. Femoral vascular catheterization in critically ill infants and children. Clin Pediatr (Phila) 1997;36:311–9. [PubMed] [Google Scholar]

249. Sheridan RL, Weber JM. Mechanical and infectious complications of central venous cannulation in children: lessons learned from a 10-year experience placing more than 1000 catheters. J Burn Care Res. 2006;27:713–8. [PubMed] [Google Scholar]

250. Stenzel JP, Green TP, Fuhrman BP, Carlson PE, Marchessault RP. Percutaneous central venous catheterization in a pediatric intensive care unit: a survival analysis of complications. Crit Care Med. 1989;17:984–8. [PubMed] [Google Scholar]

251. Goldstein AM, Weber JM, Sheridan RL. Femoral venous access is safe in burned children: an analysis of 224 catheters. J Pediatr. 1997;130:442–6. [PubMed] [Google Scholar]

252. Ramos GE, Bolgiani AN, Patino O, et al. Catheter infection risk related to the distance between insertion site and burned area. J Burn Care Rehabil. 2002;23:266–71. [PubMed] [Google Scholar]

253. Sheth NK, Franson TR, Rose HD, Buckmire FL, Cooper JA, Sohnle PG. Colonization of bacteria on polyvinyl chloride and Teflon intravascular catheters in hospitalized patients. J Clin Microbiol. 1983;18:1061–3. [PMC free article] [PubMed] [Google Scholar]

254. Maki DG, Ringer M. Evaluation of dressing regimens for prevention of infection with peripheral intravenous catheters. Gauze, a transparent polyurethane dressing, and an iodophor-transparent dressing. JAMA. 1987;258:2396–403. [PubMed] [Google Scholar]

255. Pittet D, Hugonnet S, Harbath S, et al. Effectiveness of a hospital-wide prgramme to improve compliance with hand hygiene. Lancet. 2000;356:1307–9. [PubMed] [Google Scholar]

256. Humar A, Ostromecki A, Direnfeld J, et al. Prospective randomized trial of 10% povidone-iodine versus 0.5% tincture of chlorhexidine as cutaneous antisepsis for prevention of central venous catheter infection. Clin Infect Dis. 2000;31:1001–7. [PubMed] [Google Scholar]

257. Chaiyakunapruk N, Veenstra DL, Lipsky BA, Saint S. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med. 2002;136:792–801. [PubMed] [Google Scholar]

258. Chaiyakunapruk N, Veenstra DL, Lipsky BA, Sullivan SD, Saint S. Vascular catheter site care: the clinical and economic benefits of chlorhexidine gluconate compared with povidone iodine. Clin Infect Dis. 2003;37:764–71. [PubMed] [Google Scholar]

259. Parienti JJ, du Cheyron D, Ramakers M, et al. Alcoholic povidone-iodine to prevent central venous catheter colonization: a randomized unit-crossover study. Crit Care Med. 2004;32:708–13. [PubMed] [Google Scholar]

260. Hoffmann KK, Weber DJ, Samsa GP, Rutala WA. Transparent polyurethane film as an intravenous catheter dressing. A meta-analysis of the infection risks. JAMA. 1992;267:2072–6. [PubMed] [Google Scholar]

261. Gillies D, O'Riordan E, Carr D, O'Brien I, Frost J, Gunning R. Central venous catheter dressings: a systematic review. J Adv Nurs. 2003;44:623–32. [PubMed] [Google Scholar]

262. Ruschulte H, Franke M, Gastmeier P, et al. Prevention of central venous catheter related infections with chlorhexidine gluconate impregnated wound dressings: a randomized controlled trial. Ann Hematol. 2009;88:267–72. [PubMed] [Google Scholar]

263. Veenstra DL, Saint S, Saha S, Lumley T, Sullivan SD. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis. JAMA. 1999;281:261–7. [PubMed] [Google Scholar]

264. Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. Ann Intern Med. 1997;127:257–66. [PubMed] [Google Scholar]

265. Bassetti S, Hu J, D'Agostino RB, Jr., Sherertz RJ. Prolonged antimicrobial activity of a catheter containing chlorhexidine-silver sulfadiazine extends protection against catheter infections in vivo. Antimicrob Agents Chemother. 2001;45:1535–8. [PMC free article] [PubMed] [Google Scholar]

266. Oda T, Hamasaki J, Kanda N, Mikami K. Anaphylactic shock induced by an antiseptic-coated central venous [correction of nervous] catheter. Anesthesiology. 1997;87:1242–4. [PubMed] [Google Scholar]

267. Pittaway A, Ford S. Allergy to chlorhexidine-coated central venous catheters revisited. Br J Anaesth. 2002;88:304–5. author reply 305. [PubMed] [Google Scholar]

268. Stephens R, Mythen M, Kallis P, Davies DW, Egner W, Rickards A. Two episodes of life-threatening anaphylaxis in the same patient to a chlorhexidine-sulphadiazine-coated central venous catheter. Br J Anaesth. 2001;87:306–8. [PubMed] [Google Scholar]

269. Terazawa E, Shimonaka H, Nagase K, Masue T, Dohi S. Severe anaphylactic reaction due to a chlorhexidine-impregnated central venous catheter. Anesthesiology. 1998;89:1296–8. [PubMed] [Google Scholar]

270. Jee R, Nel L, Gnanakumaran G, Williams A, Eren E. Four cases of anaphylaxis to chlorhexidine impregnated central venous catheters: a case cluster or the tip of the iceberg? Br J Anaesth. 2009;103:614–5. [PubMed] [Google Scholar]

271. Veenstra DL, Saint S, Sullivan SD. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. JAMA. 1999;282:554–60. [PubMed] [Google Scholar]

272. Tambe SM, Sampath L, Modak SM. In vitro evaluation of the risk of developing bacterial resistance to antiseptics and antibiotics used in medical devices. J Antimicrob Chemother. 2001;47:589–98. [PubMed] [Google Scholar]

273. Sampath LA, Tambe SM, Modak SM. In vitro and in vivo efficacy of catheters impregnated with antiseptics or antibiotics: evaluation of the risk of bacterial resistance to the antimicrobials in the catheters. Infect Control Hosp Epidemiol. 2001;22:640–6. [PubMed] [Google Scholar]

274. Marciante KD, Veenstra DL, Lipsky BA, Saint S. Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use. Am J Infect Control. 2003;31:1–8. [PubMed] [Google Scholar]

275. Shorr AF, Humphreys CW, Helman DL. New choices for central venous catheters: potential financial implications. Chest. 2003;124:275–84. [PubMed] [Google Scholar]

276. Hagau N, Studnicska D, Gavrus RL, Csipak G, Hagau R, Slavcovici AV. Central venous catheter colonization and catheter-related bloodstream infections in critically ill patients: a comparison between standard and silver-integrated catheters. Eur J Anaesthesiol. 2009;26:752–8. [PubMed] [Google Scholar]

277. Bong JJ, Kite P, Wilco MH, McMahon MJ. Prevention of catheter related bloodstream infection by silver iontophoretic central venous catheters: a randomised controlled trial. J Clin Pathol. 2003;56:731–5. [PMC free article] [PubMed] [Google Scholar]

278. Corral L, Nolla-Salas M, Ibanez-Nolla J, et al. A prospective, randomized study in critically ill patients using the Oligon Vantex catheter. J Hosp Infect. 2003;55:212–9. [PubMed] [Google Scholar]

279. Ranucci M, Isgro G, Giomarelli PP, et al. Impact of oligon central venous catheters on catheter colonization and catheter-related bloodstream infection. Crit Care Med. 2003;31:52–9. [PubMed] [Google Scholar]

280. Raad II, Hachem RY, Abi-Said D, et al. A prospective crossover randomized trial of novobiocin and rifampin prophylaxis for the prevention of intravascular catheter infections in cancer patients treated with interleukin-2. Cancer. 1998;82:403–11. [PubMed] [Google Scholar]

281. McKee R, Dunsmuir R, Whitby M, Garden OJ. Does antibiotic prophylaxis at the time of catheter insertion reduce the incidence of catheter-related sepsis in intravenous nutrition? J Hosp Infect. 1985;6:419–25. [PubMed] [Google Scholar]

282. Sandoe JA, Kumar B, Stoddart B, et al. Effect of extended perioperative antibiotic prophylaxis on intravascular catheter colonization and infection in cardiothoracic surgery patients. J Antimicrob Chemother. 2003;52:877–9. [PubMed] [Google Scholar]

283. Inglis GDT, Jardine LA, Davies MW. Prophylactic antibiotics to reduce morbidity and mortality in neonates with umbilical artery catheters. Cochrane Database of Systematic Reviews. 2007 Issue 4. Art. No.: CD004697. DOI: 10.1002/14651858.CD004697.pub3. [PMC free article] [PubMed] [Google Scholar]

284. Craft AP, Finer N, Barrington KJ. Vancomycin for prophylaxis against sepsis in preterm neonates. Cochrane Database of Systematic Reviews. 2000 Issue 1. Art. No.: CD001971. DOI: 10.1002/14651858.CD001971. [PMC free article] [PubMed] [Google Scholar]

285. Norden CW. Application of antibiotic ointment to the site of venous catheterization–a controlled trial. J Infect Dis. 1969;120:611–5. [PubMed] [Google Scholar]

286. Zinner SH, Denny-Brown BC, Braun P, Burke JP, Toala P, Kass EH. Risk of infection with intravenous indwelling catheters: effect of application of antibiotic ointment. J Infect Dis. 1969;120:616–9. [PubMed] [Google Scholar]

287. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med. 2001;344:11–6. [PubMed] [Google Scholar]

288. Chow JW, Yu VL. Staphylococcus aureus nasal carriage in hemodialysis patients. Its role in infection and approaches to prophylaxis. Arch Intern Med. 1989;149:1258–62. [PubMed] [Google Scholar]

289. Yu VL, Goetz A, Wagener M, et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med. 1986;315:91–6. [PubMed] [Google Scholar]

290. Casewell MW. The nose: an underestimated source of Staphylococcus aureus causing wound infection. J Hosp Infect. 1998;40:S3–11. [PubMed] [Google Scholar]

291. Hill RL, Fisher AP, Ware RJ, Wilson S, Casewell MW. Mupirocin for the reduction of colonization of internal jugular cannulae–a randomized controlled trial. J Hosp Infect. 1990;15:311–21. [PubMed] [Google Scholar]

292. Sesso R, Barbosa D, Leme IL, et al. Staphylococcus aureus prophylaxis in hemodialysis patients using central venous catheter: effect of mupirocin ointment. J Am Soc Nephrol. 1998;9:1085–92. [PubMed] [Google Scholar]

293. Boelaert JR, Van Landuyt HW, Godard CA, et al. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemias in haemodialysis patients. Nephrol Dial Transplant. 1993;8:235–9. [PubMed] [Google Scholar]

294. Netto dos Santos KR, de Souza Fonseca L, Gontijo Filho PP. Emergence of high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from Brazilian university hospitals. Infect Control Hosp Epidemiol. 1996;17:813–6. [PubMed] [Google Scholar]

295. Miller MA, Dascal A, Portnoy J, Mendelson J. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol. 1996;17:811–3. [PubMed] [Google Scholar]

296. Lok CE, Stanley KE, Hux JE, Richardson R, Tobe SW, Conly J. Hemodialysis infection prevention with polysporin ointment. J Am Soc Nephrol. 2003;14:169–79. [PubMed] [Google Scholar]

297. Yahav D, Rozen-Zvi B, Gafter-Gvili A, Leibovici L, Gafter U, Paul M. Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: systematic review and meta-analysis of randomized, controlled trials. Clin Infect Dis. 2008;47:83–93. [PubMed] [Google Scholar]

298. Labriola L, Crott R, Jadoul M. Preventing haemodialysis catheter-related bacteraemia with an antimicrobial lock solution: a meta-analysis of prospective randomized trials. Nephrol Dial Transplant. 2008;23:1666–72. [PubMed] [Google Scholar]

299. Jaffer Y, Selby NM, Taal MW, Fluck RJ, McIntyre CW. A meta-analysis of hemodialysis catheter locking solutions in the prevention of catheter-related infection. Am J Kidney Dis. 2008;51:233–41. [PubMed] [Google Scholar]

300. Safdar N, Maki DG. Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: a meta-analysis of prospective, randomized trials. Clin Infect Dis. 2006;43:474–84. [PubMed] [Google Scholar]

301. Sanders J, Pithie A, Ganly P, et al. A prospective double-blind randomized trial comparing intraluminal ethanol with heparinized saline for the prevention of catheter-associated bloodstream infection in immunosuppressed haematology patients. J Antimicrob Chemother. 2008;62:809–15. [PubMed] [Google Scholar]

302. Schinabeck MK, Ghannoum MA. Biofilm-related indwelling medical device infections. In: Pace JL, Rupp ME, Finch RG, editors. Biofilms, infection, and antimicrobial therapy. Boca Raton: Taylor and Francis; 2006. pp. 39–50. [Google Scholar]

303. Gristina AG. Biomaterial-centered infection: microbial adhesion versus tissue integration. Science. 1987;237:1588–95. [PubMed] [Google Scholar]

304. Timsit JF, Farkas JC, Boyer JM, et al. Central vein catheter-related thrombosis in intensive care patients: incidence, risks factors, and relationship with catheter-related sepsis. Chest. 1998;114:207–13. [PubMed] [Google Scholar]

305. Eastman ME, Khorsand M, Maki DG, et al. Central venous device-related infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2. Cancer. 2001;91:806–14. [PubMed] [Google Scholar]

306. Abdelkefi A, Torjman L, Ladeb S, et al. Randomized trial of prevention of catheter-related bloodstream infection by continuous infusion of low-dose unfractionated heparin in patients with hematologic and oncologic disease. J Clin Oncol. 2005;23:7864–70. [PubMed] [Google Scholar]

307. Mermel LA, Stolz SM, Maki DG. Surface antimicrobial activity of heparin-bonded and antiseptic-impregnated vascular catheters. J Infect Dis. 1993;167:920–4. [PubMed] [Google Scholar]

308. Pierce CM, Wade A, Mok Q. Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children. Intensive Care Med. 2000;26:967–72. [PubMed] [Google Scholar]

309. Appelgren P, Ransjo U, Bindslev L, Espersen F, Larm O. Surface heparinization of central venous catheters reduces microbial colonization in vitro and in vivo: results from a prospective, randomized trial. Crit Care Med. 1996;24:1482–9. [PubMed] [Google Scholar]

310. Abdelkefi A, Achour W, Ben Othman T, et al. Use of heparin-coated central venous lines to prevent catheter-related bloodstream infection. J Support Oncol. 2007;5:273–8. [PubMed] [Google Scholar]

311. Carrasco MN, Bueno A, de las Cuevas C, et al. Evaluation of a triple-lumen central venous heparin-coated catheter versus a catheter coated with chlorhexidine and silver sulfadiazine in critically ill patients. Intensive Care Med. 2004;30:633–8. [PubMed] [Google Scholar]

312. Levy JH, Hursting MJ. Heparin-induced thrombocytopenia, a prothrombotic disease. Hematol Oncol Clin North Am. 2007;21:65–88. [PubMed] [Google Scholar]

313. Weijmer MC, Debets-Ossenkopp YJ, Van De Vondervoort FJ, ter Wee PM. Superior antimicrobial activity of trisodium citrate over heparin for catheter locking. Nephrol Dial Transplant. 2002;17:2189–95. [PubMed] [Google Scholar]

314. Boraks P, Seale J, Price J, et al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br J Haematol. 1998;101:483–6. [PubMed] [Google Scholar]

315. Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med. 1990;112:423–8. [PubMed] [Google Scholar]

316. Akl EA, Karmath G, Yosuico VED, Kim SY, Barba M, Sperati F, Cook D, Schünemann H. Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters. Cochrane Database of Systematic Reviews. 2007 Issue 3. Art. No.: CD006468. DOI: 10.1002/14651858.CD006468.pub2. [PubMed] [Google Scholar]

317. Akl EA, Muti P, Schunemann HJ. Anticoagulation in patients with cancer: an overview of reviews. Pol Arch Med Wewn. 2008;118:183–93. [PubMed] [Google Scholar]

318. Klerk CP, Smorenburg SM, Buller HR. Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review. Arch Intern Med. 2003;163:1913–21. [PubMed] [Google Scholar]

319. Heaton DC, Han DY, Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern Med J. 2002;32:84–8. [PubMed] [Google Scholar]

320. Masci G, Magagnoli M, Zucali PA, et al. Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol. 2003;21:736–9. [PubMed] [Google Scholar]

321. Kuter DJ. Thrombotic complications of central venous catheters in cancer patients. Oncologist. 2004;9:207–16. [PubMed] [Google Scholar]

322. Fontaine PJ. Performance of a new softening expanding midline catheter in home intravenous therapy patients. J Intraven Nurs. 1991;14:91–9. [PubMed] [Google Scholar]

323. Harwood IR, Greene LM, Kozakowski-Koch JA, Rasor JS. New peripherally inserted midline catheter: a better alternative for intravenous antibiotic therapy in patients with cystic fibrosis. Pediatr Pulmonol. 1992;12:233–9. [PubMed] [Google Scholar]

324. Mermel LA, Parenteau S, Tow SM. The risk of midline catheterization in hospitalized patients. A prospective study. Ann Intern Med. 1995;123:841–4. [PubMed] [Google Scholar]

325. Uldall PR, Merchant N, Woods F, Yarworski U, Vas S. Changing subclavian haemodialysis cannulas to reduce infection. Lancet. 1981;1:1373. [PubMed] [Google Scholar]

326. Cook D, Randolph A, Kernerman P, et al. Central venous catheter replacement strategies: a systematic review of the literature. Crit Care Med. 1997;25:1417–24. [PubMed] [Google Scholar]

327. Cobb DK, High KP, Sawyer RG, et al. A controlled trial of scheduled replacement of central venous and pulmonary-artery catheters. N Engl J Med. 1992;327:1062–8. [PubMed] [Google Scholar]

328. Beathard GA. Management of bacteremia associated with tunneled-cuffed hemodialysis catheters. J Am Soc Nephrol. 1999;10:1045–9. [PubMed] [Google Scholar]

329. Duszak R, Jr., Haskal ZJ, Thomas-Hawkins C, et al. Replacement of failing tunneled hemodialysis catheters through pre-existing subcutaneous tunnels: a comparison of catheter function and infection rates for de novo placements and over-the-wire exchanges. J Vasc Interv Radiol. 1998;9:321–7. [PubMed] [Google Scholar]

330. Robinson D, Suhocki P, Schwab SJ. Treatment of infected tunneled venous access hemodialysis catheters with guidewire exchange. Kidney Int. 1998;53:1792–4. [PubMed] [Google Scholar]

331. Saad TF. Bacteremia associated with tunneled, cuffed hemodialysis catheters. Am J Kidney Dis. 1999;34:1114–24. [PubMed] [Google Scholar]

332. Ainsworth S, Clerihew L, McGuire W. Percutaneous central venous catheters versus peripheral cannulae for delivery of parenteral nutrition in neonates. Cochrane Database of Systematic Reviews. 2007 Issue 3. Art. No.: CD004219. DOI: 10.1002/14651858.CD004219. pub3. [PubMed] [Google Scholar]

333. Shah PS, Kalyn A, Satodia P, et al. A randomized, controlled trial of heparin versus placebo infusion to prolong the usability of peripherally placed percutaneous central venous catheters (PCVCs) in neonates: the HIP (Heparin Infusion for PCVC) study. Pediatrics. 2007;119:e284–91. [PubMed] [Google Scholar]

334. Jaar BG, Hermann JA, Furth SL, Briggs W, Powe NR. Septicemia in diabetic hemodialysis patients: comparison of incidence, risk factors, and mortality with nondiabetic hemodialysis patients. Am J Kidney Dis. 2000;35:282–92. [PubMed] [Google Scholar]

335. Powe NR, Jaar B, Furth SL, Hermann J, Briggs W. Septicemia in dialysis patients: incidence, risk factors, and prognosis. Kidney Int. 1999;55:1081–90. [PubMed] [Google Scholar]

336. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol. 1998;9:869–76. [PubMed] [Google Scholar]

337. Blot F, Chachaty E, Raynard B, Antoun S, Bourgain JL, Nitenberg G. Mechanisms and risk factors for infection of pulmonary artery catheters and introducer sheaths in cancer patients admitted to an intensive care unit. J Hosp Infect. 2001;48:289–97. [PubMed] [Google Scholar]

338. Kac G, Durain E, Amrein C, Herisson E, Fiemeyer A, Buu-Hoi A. Colonization and infection of pulmonary artery catheter in cardiac surgery patients: epidemiology and multivariate analysis of risk factors. Crit Care Med. 2001;29:971–5. [PubMed] [Google Scholar]

339. Chen YY, Yen DH, Yang YG, Liu CY, Wang FD, Chou P. Comparison between replacement at 4 days and 7 days of the infection rate for pulmonary artery catheters in an intensive care unit. Crit Care Med. 2003;31:1353–8. [PubMed] [Google Scholar]

340. Balagtas RC, Bell CE, Edwards LD, Levin S. Risk of local and systemic infections associated with umbilical vein catheterization: a prospective study in 86 newborn patients. Pediatrics. 1971;48:359–67. [PubMed] [Google Scholar]

341. Butler-O'Hara M, Buzzard CJ, Reubens L, McDermott MP, DiGrazio W, D'Angio CT. A randomized trial comparing long-term and short-term use of umbilical venous catheters in premature infants with birth weights of less than 1251 grams. Pediatrics. 2006;118:e25–35. [PubMed] [Google Scholar]

342. Scheer B, Perel A, Pfeiffer UJ. Clinical review: complications and risk factors of peripheral arterial catheters used for haemodynamic monitoring in anaesthesia and intensive care medicine. Crit Care. 2002;6:199–204. [PMC free article] [PubMed] [Google Scholar]

343. Lorente L, Santacreu R, Martin MM, Jimenez A, Mora ML. Arterial catheter-related infection of 2,949 catheters. Crit Care. 2006;10:R83. [PMC free article] [PubMed] [Google Scholar]

344. Furfaro S, Gauthier M, Lacroix J, Nadeau D, Lafleur L, Mathews S. Arterial catheter-related infections in children. A 1-year cohort analysis. Am J Dis Child. 1991;145:1037–43. [PubMed] [Google Scholar]

345. Rickard CM, Lipman J, Courtney M, Siversen R, Daley P. Routine changing of intravenous administration sets does not reduce colonization or infection in central venous catheters. Infect Control Hosp Epidemiol. 2004;25:650–5. [PubMed] [Google Scholar]

346. Hanna HA, Raad I. Blood products: a significant risk factor for long-term catheter-related bloodstream infections in cancer patients. Infect Control Hosp Epidemiol. 2001;22:165–6. [PubMed] [Google Scholar]

347. Saiman L, Ludington E, Dawson JD, et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J. 2001;20:1119–24. [PubMed] [Google Scholar]

348. Avila-Figueroa C, Goldmann DA, Richardson DK, Gray JE, Ferrari A, Freeman J. Intravenous lipid emulsions are the major determinant of coagulase-negative staphylococcal bacteremia in very low birth weight newborns. Pediatr Infect Dis J. 1998;17:10–7. [PubMed] [Google Scholar]

349. Crocker KS, Noga R, Filibeck DJ, Krey SH, Markovic M, Steffee WP. Microbial growth comparisons of five commercial parenteral lipid emulsions. J Parenter Enteral Nutr. 1984;8:391–5. [PubMed] [Google Scholar]

350. Jarvis WR, Highsmith AK. Bacterial growth and endotoxin production in lipid emulsion. J Clin Microbiol. 1984;19:17–20. [PMC free article] [PubMed] [Google Scholar]

351. Karamanoglu A, Yumuk PF, Gumus M, et al. Port needles: do they need to be removed as frequently in infusional chemotherapy? J Infus Nurs. 2003;26:239–42. [PubMed] [Google Scholar]

352. Niel-Weise BS, Daha TJ, van den Broek PJ. Is there evidence for recommending needleless closed catheter access systems in guidelines? A systematic review of randomized controlled trials. J Hosp Infect. 2006;62:406–13. [PubMed] [Google Scholar]

353. Inoue Y, Nezu R, Matsuda H, et al. Prevention of catheter-related sepsis during parenteral nutrition: effect of a new connection device. J Parenter Enteral Nutr. 1992;16:581–5. [PubMed] [Google Scholar]

354. Yebenes JC, Vidaur L, Serra-Prat M, et al. Prevention of catheter-related bloodstream infection in critically ill patients using a disinfectable, needle-free connector: a randomized controlled trial. Am J Infect Control. 2004;32:291–5. [PubMed] [Google Scholar]

355. Casey AL, Worthington T, Lambert PA, Quinn D, Faroqui MH, Elliott TS. A randomized, prospective clinical trial to assess the potential infection risk associated with the PosiFlow needleless connector. J Hosp Infect. 2003;54:288–93. [PubMed] [Google Scholar]

356. Esteve F, Pujol M, Limon E, et al. Bloodstream infection related to catheter connections: a prospective trial of two connection systems. J Hosp Infect. 2007;67:30–4. [PubMed] [Google Scholar]

357. Yebenes JC, Delgado M, Sauca G, et al. Efficacy of three different valve systems of needle-free closed connectors in avoiding access of microorganisms to endovascular catheters after incorrect handling. Crit Care Med. 2008;36:2558–61. [PubMed] [Google Scholar]

358. Menyhay SZ, Maki DG. Preventing central venous catheter-associated bloodstream infections: development of an antiseptic barrier cap for needleless connectors. Am J Infect Control. 2008;36(Suppl 174):e1–5. [PubMed] [Google Scholar]

359. Jarvis WR, Murphy C, Hall KK, et al. Health care-associated bloodstream infections associated with negative- or positive-pressure or displacement mechanical valve needleless connectors. Clin Infect Dis. 2009;49:1821–7. [PubMed] [Google Scholar]

360. Menyhay SZ, Maki DG. Disinfection of needleless catheter connectors and access ports with alcohol may not prevent microbial entry: the promise of a novel antiseptic-barrier cap. Infect Control Hosp Epidemiol. 2006;27:23–7. [PubMed] [Google Scholar]

361. Safdar N, Maki DG. Lost in translation. Infect Control Hosp Epidemiol. 2006;27:3–7. [PubMed] [Google Scholar]

362. Warren DK, Yokoe DS, Climo MW, et al. Preventing catheter-associated bloodstream infections: a survey of policies for insertion and care of central venous catheters from hospitals in the prevention epicenter program. Infect Control Hosp Epidemiol. 2006;27:8–13. [PubMed] [Google Scholar]

363. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2002;51:1–29. [PubMed] [Google Scholar]

364. Krein SL, Hofer TP, Kowalski CP, et al. Use of central venous catheter-related bloodstream infection prevention practices by US hospitals. Mayo Clin Proc. 2007;82:672–8. [PubMed] [Google Scholar]

365. Lobo RD, Levin AS, Gomes LM, et al. Impact of an educational program and policy changes on decreasing catheter-associated bloodstream infections in a medical intensive care unit in Brazil. Am J Infect Control. 2005;33:83–7. [PubMed] [Google Scholar]

366. Marschall J, Leone C, Jones M, Nihill D, Fraser VJ, Warren DK. Catheter-associated bloodstream infections in general medical patients outside the intensive care unit: a surveillance study. Infect Control Hosp Epidemiol. 2007;28:905–9. [PubMed] [Google Scholar]

367. Rosenthal VD, McCormick RD, Guzman S, Villamayor C, Orellano PW. Effect of education and performance feedback on handwashing: the benefit of administrative support in Argentinean hospitals. Am J Infect Control. 2003;31:85–92. [PubMed] [Google Scholar]

368. Gastmeier P, Geffers C. Prevention of catheter-related bloodstream infections: analysis of studies published between 2002 and 2005. J Hosp Infect. 2006;64:326–35. [PubMed] [Google Scholar]

369. Pronovost PJ, Goeschel CA, Colantuoni E, et al. Sustaining reductions in catheter related bloodstream infections in Michigan intensive care units: observational study. BMJ. 2010;340:c309. [PMC free article] [PubMed] [Google Scholar]

370. Shapey IM, Foster MA, Whitehouse T, Jumaa P, Bion JF. Central venous catheter-related bloodstream infections: improving post-insertion catheter care. J Hosp Infect. 2009;71:117–22. [PubMed] [Google Scholar]

What technique should be used to change an IV site dressing?

Use multi-directional friction to clean the site including surrounding skin to area beyond the size of the dressing. Allow skin to dry. Multi-directional friction reduces microorganisms. Cleaning beyond the size of the dressing reduces microorganisms under the dressing thus reducing risk of infection.

Why is it important to label the gauze dressing covering the site of an intravenous access device with the date time and nurses initials?

1. Why is it important to label the gauze dressing covering the site of an intravenous access device with the date, time, and nurse's initials? INCORRECT. The dressing is labeled in order to inform the nurse when the next dressing change is due.

When should an IV dressing be changed?

➢ All short peripheral intravenous site dressings must be changed every 5-7 days, and more often as indicated. ➢ The continued need for the IV site should be examined daily, and catheters should be removed if no IV therapy is planned.

How do you protect an IV site?

Keep the IV site dry. The IV site should be kept dry at all times. This helps prevent infection and accidental IV line removal.

How will the nurse minimize the risk for infection when changing a patients IV catheter site dressing?

What technique should be used to change an IV site dressing?

Why is it important to label the gauze dressing covering the site of an intravenous access device with the date time and nurses initials?

When should an IV dressing be changed?

How do you protect an IV site?

zusammenhängende Posts

When administering an IV bolus medication the nurse will best minimize the patients risk for inquiry by?

What would the nurse do to assess a patient’s risk for embolus when removing a venous access device?

Which intervention does the nurse perform in the acute care of a patient with autonomic dysreflexia?

The nurse is conducting a community education program on stress the nurse includes which information

Which behavior would the nurse leader expect all members to demonstrate when a therapy group is achieving its objective?

What should the nurse preparing to collect an admission history from parents who have recently emigrated from Russia keep in mind?

Which fine motor skill would the nurse expect when assessing the development of an infant between 10 and 12 months of age quizlet?

Which fine motor skill should the nurse anticipate when assessing an infant who is 3 months of age?

For which side effect would the nurse inform the patient to monitor after being prescribed Nystatin antifungal cream?

Which teaching instructions will a nurse provide to a patient who has been prescribed isotretinoin?

Werbung

NEUESTEN NACHRICHTEN

Which list below contains only information systems development project risk factors?

Controlling measures the of actual performance from the standard performance

Welche Elemente kommen im menschlichen Körper vor?

Mit anzusehen wenn der mann anbaut

Second Hand Kinder in der Nähe

Which of the following statements is true regarding surface-level diversity?

Wie wird man im Solarium am besten braun?

When giving a speech of presentation you should usually explain why the recipient is being given his or her award?

Wie lange ist 3 tage fieber ansteckend

Was sagt man wenn jemand in rente geht

Werbung

Populer

Werbung

Um

Legal

Hilfe

Sozial